Univariate analysis of risk factors
| Variable . | Overall survival . | Event-free survival . | Relapse rate . | Nonrelapse mortality . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| WBC at diagnosis, ×109/L (less than 30, n=42; more than 30, n=36; na=1) | 1.97 (1.08-3.58) | .03 | 1.83 (1.03-3.24) | .04 | 1.87 (0.76-4.63) | .17 | 1.87 (0.88-3.98) | .10 |
| Additional cytogenetic abnormalities (yes, n=32; no, n=33; na=14) | 0.70 (0.35-1.44) | .33 | 0.86 (0.44-1.68) | .66 | 1.33 (0.46-3.84) | .60 | 0.62 (0.26-1.49) | .28 |
| CNS disease, (yes, n= 3; no, n=63; na=13) | 1.27 (0.60-2.70) | .53 | 1.65 (0.80-3.37) | .17 | 2.59 (0.92-7.28) | .07 | 0.99 (0.36-2.68) | .98 |
| Prior radiation therapy (yes, n=13; no n=61; na=5) | 2.02 (0.99-4.15) | .05 | 1.81 (0.89-3.68) | .10 | 1.25 (0.36-4.32) | .72 | 2.25 (0.94-5.36) | .07 |
| Age at HCT (younger than 36 y, n=39; 36 y or older, n=40) | 1.19 (0.65-2.16) | .57 | 1.29 (0.72-2.29) | .39 | 0.97 (0.39-2.39) | .95 | 1.66 (0.78-3.51) | .19 |
| Disease status at HCT (CR1, n=49; beyond CR1, n=30) | 2.14 (1.17-3.91) | .01 | 1.98 (1.11-3.52) | .02 | 1.90 (0.76-4.77) | .17 | 2.12 (0.99-4.53) | .05 |
| Source of HCs (bone marrow, n=43; peripheral blood, n=36) | 1.04 (0.57-1.90) | .89 | .91 (.51-1.62) | .75 | 0.83 (0.33-2.06) | .69 | 0.93 (0.44-1.98) | .85 |
| Acute GVHD* (yes, n=26; no, n=51) | 1.88 (1.03-3.41) | .04 | 2.05 (1.16-3.64) | .01 | 1.32 (0.50-3.51) | .57 | 2.72 (1.29-5.77) | <.01 |
| Chronic GVHD† (yes, n=25; no, n=42) | 0.81 (0.39-1.67) | .57 | 0.69 (0.35-1.37) | .29 | 0.71 (0.28-1.79) | .46 | 0.83 (0.30-2.29) | .72 |
| Variable . | Overall survival . | Event-free survival . | Relapse rate . | Nonrelapse mortality . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| WBC at diagnosis, ×109/L (less than 30, n=42; more than 30, n=36; na=1) | 1.97 (1.08-3.58) | .03 | 1.83 (1.03-3.24) | .04 | 1.87 (0.76-4.63) | .17 | 1.87 (0.88-3.98) | .10 |
| Additional cytogenetic abnormalities (yes, n=32; no, n=33; na=14) | 0.70 (0.35-1.44) | .33 | 0.86 (0.44-1.68) | .66 | 1.33 (0.46-3.84) | .60 | 0.62 (0.26-1.49) | .28 |
| CNS disease, (yes, n= 3; no, n=63; na=13) | 1.27 (0.60-2.70) | .53 | 1.65 (0.80-3.37) | .17 | 2.59 (0.92-7.28) | .07 | 0.99 (0.36-2.68) | .98 |
| Prior radiation therapy (yes, n=13; no n=61; na=5) | 2.02 (0.99-4.15) | .05 | 1.81 (0.89-3.68) | .10 | 1.25 (0.36-4.32) | .72 | 2.25 (0.94-5.36) | .07 |
| Age at HCT (younger than 36 y, n=39; 36 y or older, n=40) | 1.19 (0.65-2.16) | .57 | 1.29 (0.72-2.29) | .39 | 0.97 (0.39-2.39) | .95 | 1.66 (0.78-3.51) | .19 |
| Disease status at HCT (CR1, n=49; beyond CR1, n=30) | 2.14 (1.17-3.91) | .01 | 1.98 (1.11-3.52) | .02 | 1.90 (0.76-4.77) | .17 | 2.12 (0.99-4.53) | .05 |
| Source of HCs (bone marrow, n=43; peripheral blood, n=36) | 1.04 (0.57-1.90) | .89 | .91 (.51-1.62) | .75 | 0.83 (0.33-2.06) | .69 | 0.93 (0.44-1.98) | .85 |
| Acute GVHD* (yes, n=26; no, n=51) | 1.88 (1.03-3.41) | .04 | 2.05 (1.16-3.64) | .01 | 1.32 (0.50-3.51) | .57 | 2.72 (1.29-5.77) | <.01 |
| Chronic GVHD† (yes, n=25; no, n=42) | 0.81 (0.39-1.67) | .57 | 0.69 (0.35-1.37) | .29 | 0.71 (0.28-1.79) | .46 | 0.83 (0.30-2.29) | .72 |
HR indicates hazard ratio; WBC, white blood cell count; na, data not available; CNS, central nervous system; HC, hematopoietic cell; HCT, hematopoietic cell transplantation; and GVHD, graft-versus-host disease.
Two patients died before engraftment.
Missing cGVHD data for 1 patient, and 11 patients died within 100 days.